 Shares of Turning Point Therapeutics Inc. TPTX, 2.21 more than doubled, up 116.7, in premarket trading Friday, after the clinical-stage oncology company agreed to be acquired by biopharmaceutical company Bristol Myers Squibb Co. BMY, 0.15 in an all-cash deal valuing Turning Point at about 3.77 billion. Bristol Myers stock was little changed ahead of the open. 